08 November 2023
08 November 2023
NICE is also working on incorporating real-world and AI-generated evidence into medicine evaluation submissions.
At the BIO-Europe conference, experts said smaller oncology biotechs need to explore alternate financing strategies for pipeline development.
At BIO-Europe 2023, experts said competition from the US and China and proposed European legislation are hurdles for this sector.
The parties will assess zanidatamab as a monotherapy and along with other medicines for a number of tumour types and stages.
Evotec is entitled to receive milestone and royalty payments contingent on the success of the programmes.
SciClone will be responsible for the development and commercialisation of Orserdu in the country.
Total product sales excluding Veklury grew by 5% to $6.35bn from $6.05bn in Q3 2022.
Merging industry-leading business intelligence & award-winning journalism, this is an unrivalled opportunity for engagement with B2B professionals across a network of 40+ leading media websites.
With only a few approved drugs currently available to treat DN by means other than regulation of blood pressure, innovator products that can treat by targeting other factors such as treatment of dyslipidemia, hypertension, or angiotensin inhibition, among others, is a key area of R&D in the DN space and is likely to pave the way for novel therapies in the near future. However, the treatment landscape is expected to remain unchanged due to limited availability of products in the late-stage pipeline currently.
Give your business an edge with our leading industry insights.
